Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

ANTA PHAR
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -40,4 M
Net income 2017 -34,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 9,87 M
EBIT 2018 -41,5 M
Net income 2018 -41,7 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 1,83x
Capitalization 18,1 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis.It... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
10/04 ANTHERA PHARMACEUTICALS INC : Today's Research Reports on Trending Tickers: Anth..
09/08 ANTHERA PHARMACEUTICALS : Surpasses 50% Milestone for Screening of Patients in R..
09/07 Anthera Pharmaceuticals Surpasses 50% Milestone for Screening of Patients in ..
09/06 ANTHERA PHARMACEUTICALS : to Present at Rodman & Renshaw's 18th Annual Global In..
09/06 Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Gl..
09/05 ANTHERA PHARMACEUTICALS : to Participate in the Citi 12th Annual Biotech Confere..
08/28 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Financial Statements a..
08/28 ANTHERA PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (f..
08/28 Anthera Announces Top Line Final Data from the Extension Period of the Phase ..
08/14 Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura w..
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 5
Average target price 6,75 $
Spread / Average Target 307%
EPS Revisions
Managers
NameTitle
John Craig Thompson President, Chief Executive Officer & Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
William R. Shanahan Chief Medical Officer
David E. Thompson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR18
GILEAD SCIENCES11.73%104 487
REGENERON PHARMACEUTICALS19.69%47 079
VERTEX PHARMACEUTICALS110.07%39 018
ACTELION23.81%29 869
GENMAB14.75%12 912